ClariVest Asset Management LLC Raises Position in Emergent Biosolutions, Inc. (EBS)
ClariVest Asset Management LLC increased its stake in Emergent Biosolutions, Inc. (NYSE:EBS) by 32.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,433 shares of the biopharmaceutical company’s stock after purchasing an additional 20,842 shares during the quarter. ClariVest Asset Management LLC owned 0.20% of Emergent Biosolutions worth $3,415,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Riverhead Capital Management LLC boosted its holdings in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 587 shares during the last quarter. First Quadrant L P CA purchased a new stake in Emergent Biosolutions in the third quarter worth approximately $157,000. Creative Planning boosted its holdings in Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 55 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Emergent Biosolutions in the third quarter worth approximately $191,000. Institutional investors own 86.09% of the company’s stock.
Several research analysts have weighed in on EBS shares. Wells Fargo & Company reiterated an “outperform” rating and issued a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Wednesday, October 25th. Finally, BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $45.00.
Emergent Biosolutions, Inc. (NYSE EBS) traded down $0.57 on Monday, reaching $37.77. 617,300 shares of the company’s stock traded hands, compared to its average volume of 332,304. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. Emergent Biosolutions, Inc. has a fifty-two week low of $25.96 and a fifty-two week high of $44.86. The company has a market capitalization of $1,563.50, a P/E ratio of 19.98, a PEG ratio of 1.04 and a beta of 1.22.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. During the same period last year, the firm earned $0.56 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. research analysts expect that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current year.
In other news, Chairman Fuad El-Hibri sold 40,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total transaction of $1,614,800.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $37.21, for a total transaction of $558,150.00. Following the sale, the chief executive officer now owns 219,134 shares in the company, valued at $8,153,976.14. The disclosure for this sale can be found here. Insiders sold 255,210 shares of company stock worth $10,157,974 over the last quarter. Insiders own 16.50% of the company’s stock.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.